GABA Type A Receptor Activation in the Allosteric Coagonist Model Framework: Relationship between EC50 and Basal Activity

被引:31
作者
Akk, Gustav [1 ,2 ]
Shin, Daniel J. [1 ]
Germann, Allison L. [1 ]
Steinbach, Joe Henry [1 ,2 ]
机构
[1] Washington Univ, Sch Med, Dept Anesthesiol, Campus Box 8054,660 S Euclid Ave, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Taylor Family Inst Innovat Psychiat Res, St Louis, MO USA
基金
美国国家卫生研究院;
关键词
ACETYLCHOLINE-RECEPTOR; SINGLE-CHANNEL; BENZODIAZEPINES MODULATE; GLYCINE RECEPTORS; PLAUSIBLE MODEL; END-PLATE; BINDING; MECHANISM; PROPOFOL; SUBUNIT;
D O I
10.1124/mol.117.110569
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The concerted transition model for multimeric proteins is a simple formulation for analyzing the behavior of transmitter-gated ion channels. Weused the model to examine the relationship between the EC50 for activation of the GABA type A (GABA(A)) receptor by the transmitter GABA and basal activity employing concatemeric ternary GABA(A) receptors expressed in Xenopus oocytes. Basal activity, reflecting the receptor function in the absence of the transmitter, can be changed either by mutation to increase constitutive activity or by the addition of a second agonist (acting at a different site) to increase background activity. The model predicts that either mechanism for producing a change in basal activity will result in identical effects on the EC50. We examined receptor activation by GABA while changing the level of basal activity with the allosterically acting anesthetics propofol, pentobarbital, or alfaxalone. We found that the relationship between EC50 and basal activity was well described by the concerted transition model. Changes in the basal activity by gain-of-function mutations also resulted in predictable changes in the EC50. Finally, we altered the number of GABA-binding sites by a mutation and again found that the relationship could be well described by the model. Overall, the results support the idea that interactions between the transmitter GABA and the allosteric agonists propofol, pentobarbital, or alfaxalone can be understood as reflecting additive and independent free energy changes, without assuming any specific interactions.
引用
收藏
页码:90 / 100
页数:11
相关论文
共 45 条
[1]   Pregnenolone sulfate block of GABAA receptors:: mechanism and involvement of a residue in the M2 region of the α subunit [J].
Akk, G ;
Bracamontes, J ;
Steinbach, JH .
JOURNAL OF PHYSIOLOGY-LONDON, 2001, 532 (03) :673-684
[2]   Activation and Modulation of Concatemeric GABA-A Receptors Expressed in Human Embryonic Kidney Cells [J].
Akk, Gustav ;
Li, Ping ;
Bracamontes, John ;
Steinbach, Joe Henry .
MOLECULAR PHARMACOLOGY, 2009, 75 (06) :1400-1411
[3]   GABA(A) RECEPTOR NEEDS 2 HOMOLOGOUS DOMAINS OF THE BETA-SUBUNIT FOR ACTIVATION BY GABA BUT NOT BY PENTOBARBITAL [J].
AMIN, J ;
WEISS, DS .
NATURE, 1993, 366 (6455) :565-569
[4]   Thinking in cycles: MWC is a good model for acetylcholine receptor-channels [J].
Auerbach, Anthony .
JOURNAL OF PHYSIOLOGY-LONDON, 2012, 590 (01) :93-98
[5]  
Baumann SW, 2003, J NEUROSCI, V23, P11158
[6]   Forced subunit assembly in α1β2γ2 GABAA receptors -: Insight into the absolute arrangement [J].
Baumann, SW ;
Baur, R ;
Sigel, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (48) :46020-46025
[7]   Slow phases of GABAA receptor desensitization:: structural determinants and possible relevance for synaptic function [J].
Bianchi, MT ;
Macdonald, RL .
JOURNAL OF PHYSIOLOGY-LONDON, 2002, 544 (01) :3-18
[8]   Occupation of Either Site for the Neurosteroid Allopregnanolone Potentiates the Opening of the GABAA Receptor Induced from Either Transmitter Binding Site [J].
Bracamontes, John ;
McCollum, Megan ;
Esch, Caroline ;
Li, Ping ;
Ann, Jason ;
Steinbach, Joe Henry ;
Akk, Gustav .
MOLECULAR PHARMACOLOGY, 2011, 80 (01) :79-86
[9]   Steroid Interaction with a Single Potentiating Site Is Sufficient to Modulate GABA-A Receptor Function [J].
Bracamontes, John R. ;
Steinbach, Joe Henry .
MOLECULAR PHARMACOLOGY, 2009, 75 (04) :973-981
[10]   Confronting Racism in Chemistry Journals [J].
Burrows, Cynthia J. ;
Huang, Jiaxing ;
Wang, Shu ;
Kim, Hyun Jae ;
Meyer, Gerald J. ;
Schanze, Kirk ;
Lee, T. Randall ;
Lutkenhaus, Jodie L. ;
Kaplan, David ;
Jones, Christopher ;
Bertozzi, Carolyn ;
Kiessling, Laura ;
Mulcahy, Mary Beth ;
Lindsley, Craig W. ;
Finn, M. G. ;
Blum, Joel D. ;
Kamat, Prashant ;
Choi, Wonyong ;
Snyder, Shane ;
Aldrich, Courtney C. ;
Rowan, Stuart ;
Liu, Bin ;
Liotta, Dennis ;
Weiss, Paul S. ;
Zhang, Deqing ;
Ganesh, Krishna N. ;
Atwater, Harry A. ;
Gooding, J. Justin ;
Allen, David T. ;
Voigt, Christopher A. ;
Sweedler, Jonathan ;
Schepartz, Alanna ;
Rotello, Vincent ;
Lecommandoux, Sebastien ;
Sturla, Shana J. ;
Hammes-Schiffer, Sharon ;
Buriak, Jillian ;
Steed, Jonathan W. ;
Wu, Hongwei ;
Zimmerman, Julie ;
Brooks, Bryan ;
Savage, Phillip ;
Tolman, William ;
Hofmann, Thomas F. ;
Brennecke, Joan F. ;
Holme, Thomas A. ;
Merz, Kenneth M., Jr. ;
Scuseria, Gustavo ;
Jorgensen, William ;
Georg, Gunda I. .
MOLECULAR PHARMACEUTICS, 2020, 17 (07) :2229-2231